Leveraging advanced nonlinear light scattering, Oryl Photonics, which was founded by Orly Tarun and Nathan Dupertuis, has developed a laboratory instrument, an advanced form of laser-based light scattering, to measure how drugs dissolve in liquids, providing critical information for the R&D of pharmaceutical and biotechnological companies while saving precious resources.

The startup’s technology will be instrumental in the recently launched FASS (Fast and Accurate Solubility for Sustainability) project, led by EU-OPENSCREEN ERIC, the European research infrastructure for early drug discovery and chemical biology with its central office in Germany. Other consortium members are Fachhochschule Nordwestschweiz (FHNW) and ALPhANOV, a research and technology organization based in France. This consortium brings complementary expertise in photonics and laser technologies, drug screening and discovery, and pharmaceutical formulation.

Scheduled to last for 30 months, the project aims to accelerate solubility measurement through its rapid, sensitive and accurate laser-based light scattering that requires the least quantity of compounds. The instrument is based on the ‘Solvent Redistribution’ method, the world’s-first solution that will disrupt the way solubility measurement is performed. The laboratory instrument created by Oryl Photonics provides a straightforward analysis and automated solubility testing process for pharmaceutical and biotechnological companies while saving precious compounds compared to existing technologies. It also reduces drastically the environmental impact with a lower consumption of chemicals, electricity and consumables, hence giving its name – Fast and Accurate Solubility for Sustainability – to the project.

The project has received an EIC Transition grant of € 2.5 M to enable the consortium to deliver this disruptive and sustainable solubility measurement instrument to the market. The grant will be instrumental for technological maturation, customer development, exploration of value-added applications of the technology in drug discovery and development and to improve market competitiveness, positioning and credibility.

“This grant will accelerate the development and market entry of our laboratory instrument. Oryl Photonics is excited to make a world impact through its light-scattering-based technology that fills a gap in the market offering of solubility measurement. The output of the grant will empower researchers in the pharmaceutical, chemical and life sciences industries to achieve more in their work, with sustainability and performance in mind”, shares Orly Tarun, CEO & Co-founder of Oryl Photonics.

(www.startupticker.ch)